{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NPDR+-+Non+Proliferative+Diabetic+Retinopathy&page=2", "query": { "condition": "NPDR - Non Proliferative Diabetic Retinopathy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NPDR+-+Non+Proliferative+Diabetic+Retinopathy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T09:14:32.807Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05383209", "title": "Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonproliferative Diabetic Retinopathy" ], "interventions": [ { "name": "EYP-1901", "type": "DRUG" }, { "name": "Sham IVT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EyePoint Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2022-09-28", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Huntington Beach, California • Oxnard, California + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383209" }, { "nct_id": "NCT00664183", "title": "A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Vitreosolve", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitreoretinal Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 400, "start_date": "2008-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-10-20", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Santa Ana, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00664183" }, { "nct_id": "NCT05066230", "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2021-09-07", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05066230" }, { "nct_id": "NCT01880372", "title": "The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Moderate Non-proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "Alpha Lipoic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Ferris State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2013-09", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 2, "location_summary": "Big Rapids, Michigan • Grand Rapids, Michigan", "locations": [ { "city": "Big Rapids", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01880372" }, { "nct_id": "NCT04692688", "title": "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy", "Diabetic Macular Edema", "NPDR - Non Proliferative Diabetic Retinopathy", "PDR - Proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "APX3330", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocuphire Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2021-04-08", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692688" }, { "nct_id": "NCT05695417", "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "OTX-TKI", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocular Therapeutix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-01-15", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-12-08", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Lemont", "state": "Illinois" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695417" }, { "nct_id": "NCT07354477", "title": "Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-proliferative Diabetic Retinopathy (NPDR)", "Open-angle Glaucoma (OAG)", "Normal Tension Glaucoma (NTG)" ], "interventions": [ { "name": "QLS-111 Ophthalmic Solution (0.015%)", "type": "DRUG" }, { "name": "QLS-111 Ophthalmic Solution (0.075%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qlaris Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-20", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07354477" }, { "nct_id": "NCT01646047", "title": "Diabetes Visual Function Supplement Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus - Type 1", "Diabetes Mellitus - Type 2", "Non-proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "multi-component nutritional supplement capsules", "type": "DIETARY_SUPPLEMENT" }, { "name": "multi-component dietary supplement", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "ZeaVision, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646047" }, { "nct_id": "NCT04722991", "title": "Non-proliferative Diabetic Retinopathy Treated With Runcaciguat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Runcaciguat (BAY1101042)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2021-03-17", "completion_date": "2024-04-22", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 11, "location_summary": "Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more", "locations": [ { "city": "Modesto", "state": "California" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04722991" }, { "nct_id": "NCT02681809", "title": "A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy", "Posterior Vitreous Detachment", "Disease Progression" ], "interventions": [ { "name": "ocriplasmin 0.0625mg", "type": "DRUG" }, { "name": "ocriplasmin 0.125mg", "type": "DRUG" }, { "name": "Sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ThromboGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-12", "completion_date": "2019-11-18", "has_results": true, "last_update_posted_date": "2020-12-16", "last_synced_at": "2026-06-11T09:14:32.807Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Campbell, California • Irvine, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02681809" } ] }